Test predicts obesity patients’ response to Ozempic


A new study has demonstrated the clinical utility of a machine-learning gene risk score biomarker to predict patient response to Ozempic (semaglutide) and reduce variability.

The study ‘Performance of a Machine-Learning Gene Risk Score Biomarker on Predicting Response to Semaglutide’ was led by the Mayo Clinic and presented at Digestive Disease Week 2024.

It analysed the performance of the MyPhenome Hungry Gut test from Phenomix Sciences in 84 participants with obesity who were prescribed semaglutide.

The patients were tested using the MyPhenome test and the data analysed using its Machine-Learning Gene Risk Score (ML-GRS) to categorize them as Hungry Gut positive or negative. The Hungry Gut phenotype refers to patients who have altered postprandial satiety, meaning food passes through the stomach more rapidly causing them to feel hungry sooner after a meal.

The findings revealed that individuals identified as Hungry Gut positive achieved 19.5% total-body weight loss (TBWL) at the 12-month mark, while the negative counterparts experienced only 10% TBWL.

Dr Hurtado Andrade, Principle Investigator in the study said, “Our data support that obesity has a strong genetic and biological basis that varies within patients living with obesity. Furthermore, our results underscore the potential of individualising therapy to improve outcomes that will ultimately translate into improved health.”

High demand for Ozempic and Wegovy

Obesity phenotypes are the combination of genes and other biometric data that cause obesity, first discovered by Phenomix’s co-founders and Mayo Clinic physicians, Drs Andres Acosta and Michael Camilleri.

Mark Bagnall, CEO of Phenomix Sciences, said: “Demand for semaglutide marketed as Ozempic and Wegovy, is at an all-time high; this study showed an ability to identify responders to semaglutide using our test. We are excited about what lies ahead in precision medicine for obesity and are hopeful our test will be a pivotal tool for clinicians across the US.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free